Table 3. Relationship between S100A11 expression and clinicopathologic characteristics of stage I lung adenocarcinomas.
| Subjects | No. | Expression score (median) | P-value |
|---|---|---|---|
| Age | |||
| <65 | 63 | 1.20 | P = 0.617 |
| > = 65 | 116 | 1.30 | |
| Gender | |||
| Male | 89 | 1.20 | P = 0.845 |
| Female | 90 | 1.30 | |
| Histologic Grade | |||
| WEL | 42 | 1.00 | P = 0.021 |
| MOD | 90 | 1.30 | |
| POR | 47 | 1.50 | |
| Histologic Subtype | |||
| AIS/MIA | 42 | 1.00 | P = 0.064 |
| LEP | 43 | 1.20 | |
| CAN | 59 | 1.50 | |
| PAP/MPAP | 17 | 1.40 | |
| SOL | 12 | 1.25 | |
| MUC | 6 | 1.35 | |
| Lymphatic or vascular involvement | |||
| Absent | 129 | 1.20 | P = 0.026 |
| Present | 50 | 1.50 |
No., number of cases; WEL, well differentiated; MOD, moderately differentiated; POR, poorly differentiated carcinomas; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LEP, lepidic predominant; ACN, acinar predominant; PAP, papillary predominant, SOL, solid predominant; MUC, invasive mucinous adenocarcinoma.
Histologic subtypes were classified according to the 2011 IASLC/ ATS/ETS classification of lung adenocarcinoma.
P, significant level for Mann-Whitney or Kruskal-Wallis test.